| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/29/1999 | WO1999037304A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS |
| 07/29/1999 | WO1999037303A1 Combination of a gaba-a alpha 2/3 agonist and a selective serotonin reuptake inhibitor |
| 07/29/1999 | WO1999037302A1 Extended release tiagabine formulations with reduced side-effects |
| 07/29/1999 | WO1999037301A1 New use for pain management |
| 07/29/1999 | WO1999037300A1 Utilization of powder preparations containing hydroxypyridones for treating leg ulcers and decubitus ulcers |
| 07/29/1999 | WO1999037298A1 Compositions and methods for treating autoimmune diseases |
| 07/29/1999 | WO1999037297A1 Pig appeasing pheromones to decrease stress, anxiety and aggressiveness |
| 07/29/1999 | WO1999037296A1 Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
| 07/29/1999 | WO1999037295A1 Method and composition for skin treatment |
| 07/29/1999 | WO1999037294A2 Mitochondria protecting agents for treating mitochondria associated diseases |
| 07/29/1999 | WO1999037293A2 Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders |
| 07/29/1999 | WO1999037292A2 Carbonic anhydrase inhibitor for increasing oxygen tension in the optic nerve and retina |
| 07/29/1999 | WO1999037291A2 Utilization of substituted sulfonamides as antiviral agents and novel substances |
| 07/29/1999 | WO1999037290A1 Novel dosage form |
| 07/29/1999 | WO1999037289A1 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
| 07/29/1999 | WO1999037287A1 Bioactive glass treatment of inflammation in skin conditions |
| 07/29/1999 | WO1999037286A1 Fluorometholone suspension eye drops |
| 07/29/1999 | WO1999037167A2 Process of improving the stability of vitamin d in a nutritional product containing hydrolyzed protein and product produced thereby |
| 07/29/1999 | WO1999037155A1 Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
| 07/29/1999 | WO1999037151A1 Method and compositions for promotion of wound healing |
| 07/29/1999 | WO1999037150A1 Transcription therapy for cancers |
| 07/29/1999 | WO1999037149A1 Methods of treating cytotoxic damage |
| 07/29/1999 | WO1999030695A8 Substituted amidino compounds in the treatment of chronic obstructive pulmonary disease |
| 07/29/1999 | WO1999025360A3 Progestogen-antiprogestogen regimens |
| 07/29/1999 | WO1999025347A3 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction |
| 07/29/1999 | WO1999021617A3 Allosteric adenosine receptor modulators |
| 07/29/1999 | WO1999020755A3 Novel cytokine receptors |
| 07/29/1999 | WO1999018956A9 12(s)-hete receptor blockers |
| 07/29/1999 | WO1999017756A3 Method for preventing transplant rejection |
| 07/29/1999 | WO1999015183A9 PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES |
| 07/29/1999 | WO1999012968A3 Chemokine peptides, variants, derivatives and analogs, their use in methods to inhibit or augment an inflammatory response |
| 07/29/1999 | WO1999012951A9 Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases |
| 07/29/1999 | WO1999012532A3 Piperidine derivatives against malaria |
| 07/29/1999 | WO1999008500A3 New crystalline form of omeprazole |
| 07/29/1999 | WO1999002162A9 Cyclin dependent kinase inhibiting purine derivatives |
| 07/29/1999 | WO1998059063A3 Bovine adenovirus type 3 genome |
| 07/29/1999 | WO1998050530A3 Enzymatic nucleic acids: synthesis, selection and use |
| 07/29/1999 | DE19802708A1 Use of 1-hydroxy-2-pyridone compounds with powder base for treatment of lower leg ulcers and decubitus ulcers |
| 07/29/1999 | DE19802539A1 Protective creams for preventing contact dermatitis caused by divalent metals, especially nickel, cobalt or copper |
| 07/29/1999 | DE19802450A1 New saccharide compounds useful in treating schizophrenia |
| 07/29/1999 | DE19802437A1 Use of N-aminophenyl sulfonamides for treating or preventing viral infections, particularly herpes |
| 07/29/1999 | DE19802436A1 New N-aryl sulfonamides as antiviral agents, particularly against cytomegalovirus, e.g. in patients with acquired immune deficiency syndrome |
| 07/29/1999 | DE19802327A1 Synergistic analgesic composition containing 1-phenyl-cyclohexene and aminobutyric acid derivatives |
| 07/29/1999 | DE19802239A1 New oxazolidinone derivatives useful as antimicrobial agents against Gram-positive and some Gram-negative bacteria, mycobacteria, etc. |
| 07/29/1999 | DE19802235A1 New oxazolidinone derivatives useful as antibacterial agents for treating local or systemic infections in humans or animals |
| 07/29/1999 | CA2325002A1 Method and compositions for promotion of wound healing |
| 07/29/1999 | CA2320624A1 Mutants of il-16, processes for their production, and their use |
| 07/29/1999 | CA2319318A1 Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl |
| 07/29/1999 | CA2319199A1 Compositions comprising d-chiro-inositol for treating metabolic diseases characterized by hyperinsulinemia, hyperandrogenism, hyperlipidemia and/or anovulation |
| 07/29/1999 | CA2319158A1 Process of improving the stability of vitamin d in a nutritional product containing hydrolyzed protein and product produced thereby |
| 07/29/1999 | CA2319131A1 Mitochondria protecting agents for treating mitochondria associated diseases |
| 07/29/1999 | CA2319077A1 Chemokine receptor antagonists and methods of use therefor |
| 07/29/1999 | CA2318969A1 Oxazolidinone combinatorial libraries, compositions and methods of preparation |
| 07/29/1999 | CA2318952A1 Triazolo-pyridazine derivatives as ligands for gaba receptors |
| 07/29/1999 | CA2318935A1 Phagocytosis genes and uses thereof |
| 07/29/1999 | CA2318842A1 Quinoline derivatives as antibacterials |
| 07/29/1999 | CA2318743A1 Novel molecules of the tnf receptor superfamily and uses therefor |
| 07/29/1999 | CA2318642A1 Fluorometholone ophthalmic suspension |
| 07/29/1999 | CA2318639A1 Vla-4 antagonists |
| 07/29/1999 | CA2318580A1 Pharmaceutically active compounds and methods of use thereof |
| 07/29/1999 | CA2318448A1 Extended release tiagabine formulations with reduced side-effects |
| 07/29/1999 | CA2318352A1 Diagnosis and treatment of aur1 and/or aur2 related disorders |
| 07/29/1999 | CA2318268A1 Pharmaceutically active morpholinol |
| 07/29/1999 | CA2318257A1 Novel dosage form |
| 07/29/1999 | CA2318221A1 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| 07/29/1999 | CA2318182A1 Novel naphthyl-substituted and anilide-substituted sulfonamides |
| 07/29/1999 | CA2318100A1 Chemokine receptor antagonists and methods of use therefor |
| 07/29/1999 | CA2318088A1 Chemokine receptor antagonists and methods of use therefor |
| 07/29/1999 | CA2317839A1 Inhibition of cytokine production |
| 07/29/1999 | CA2317744A1 Cellulose derivatives and colorectal cancer risk reduction |
| 07/29/1999 | CA2317740A1 Sulphonamide derivatives for treatment of cns disorders |
| 07/29/1999 | CA2317577A1 Methods of decreasing or preventing pain using spicamycin or derivatives thereof |
| 07/29/1999 | CA2317546A1 2,3,4,5-tetrahydro-1h-¬1,4|-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors |
| 07/29/1999 | CA2317486A1 Triazolo-pyridazine derivatives as ligands for gaba receptors |
| 07/29/1999 | CA2317484A1 Triazolo-pyridazine derivatives as ligands for gaba receptors |
| 07/29/1999 | CA2317457A1 Potassium channel inhibitors |
| 07/29/1999 | CA2317424A1 Combination of a gaba-a alpha 2/3 agonist and a selective serotonin reuptake inhibitor |
| 07/29/1999 | CA2317422A1 Triazolo-pyridazine derivatives as ligands for gaba receptors |
| 07/29/1999 | CA2317121A1 Carbonic anhydrase inhibitor for increasing oxygen tension in the optic nerve and retina |
| 07/29/1999 | CA2315763A1 Triazolo-pyridazine derivatives as ligands for gaba receptors |
| 07/29/1999 | CA2315213A1 Triazolo-pyridazine derivatives as ligands for gaba receptors |
| 07/29/1999 | CA2312350A1 Alternate method for acylating 10-deacetylbaccatin iii selectively at the c-10 position |
| 07/29/1999 | CA2309354A1 Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
| 07/29/1999 | CA2284864A1 Dialkyl ureas as calcitonin mimetics |
| 07/29/1999 | CA2260499A1 Pharmaceutical compositions for the treatment of ischemic brain damage |
| 07/28/1999 | EP0931830A2 Cytopathic viruses for therapy and phophylaxis of neoplasia |
| 07/28/1999 | EP0931793A1 Monoclonal antibody specific for the activated coagulation factor VII (FVIIa) and its use |
| 07/28/1999 | EP0931788A2 Metalloprotease inhibitors |
| 07/28/1999 | EP0931786A2 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| 07/28/1999 | EP0931551A1 Diagnostics and therapeutics for transmissible spongiform encephalopathy and method for the manufacture of non-infective blood products and tissue derived products |
| 07/28/1999 | EP0931548A2 Antifibrotic agent |
| 07/28/1999 | EP0931547A1 Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions |
| 07/28/1999 | EP0931545A2 Droloxifene pharmaceutical compositions |
| 07/28/1999 | EP0931544A2 NF-kB activity inhibitor |
| 07/28/1999 | EP0931542A1 Cosmetic composition containing phloroglucinol |
| 07/28/1999 | EP0931541A1 Composition containing a procysteine and polyol combination |
| 07/28/1999 | EP0931149A2 A novel haemopoietin receptor and genetic sequences encoding same |
| 07/28/1999 | EP0931147A1 ANTI-ErbB2 ANTIBODIES |
| 07/28/1999 | EP0931145A1 Ptx sensitive g proteins, the production and use thereof |
| 07/28/1999 | EP0931144A1 Novel human phospholemman-like protein |